| 前收盘价格 | 12.64 |
| 收盘价格 | 12.78 |
| 成交量 | 361,137 |
| 平均成交量 (3个月) | 743,020 |
| 市值 | 218,059,504 |
| 市盈率 (P/E TTM) | 4.54 |
| 价格/销量 (P/S) | 3.00 |
| 股市价格/股市净资产 (P/B) | 4.62 |
| 52周波幅 |
| 稀释每股收益 (EPS TTM) | -7.57 |
| 总债务/股东权益 (D/E MRQ) | 333.06% |
| 流动比率 (MRQ) | 4.71 |
| 营业现金流 (OCF TTM) | -65.65 M |
| 杠杆自由现金流 (LFCF TTM) | -48.59 M |
| 资产报酬率 (ROA TTM) | -33.79% |
| 股东权益报酬率 (ROE TTM) | -267.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Q32 Bio Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.00 |
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 6.57% |
| 机构持股比例 | 73.27% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Monimus Capital Management, Lp | 31 Mar 2026 | 134,310 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合